^
    3d
    A multicenter prospective randomized controlled study of quadruplet regimen in newly diagnosed transplant-ineligible high-risk multiple myeloma patients (ChiCTR2600116772)
    P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    3d
    A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with chronic immune thrombocytopenia (ChiCTR2500115452)
    P1/2, N=75, Completed, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; CASI Pharmaceuticals (China) Co., Ltd.
    New P1/2 trial
    5d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=292, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone
    5d
    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2025
    Trial completion • Trial completion date
    |
    lenalidomide • Darzalex (daratumumab)
    7d
    TAK-079-1006: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy (clinicaltrials.gov)
    P1, N=17, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    mezagitamab (TAK-079)
    10d
    Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. (PubMed, Nephrol Dial Transplant)
    We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context...Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR...In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
    Journal
    |
    IL6 (Interleukin 6) • CD40LG (CD40 ligand)
    |
    Blincyto (blinatumomab) • Darzalex (daratumumab) • Tecvayli (teclistamab-cqyv)
    10d
    Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=122, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Darzalex (daratumumab)
    13d
    TRANSPIRE: A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (clinicaltrials.gov)
    P2, N=81, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    felzartamab (MOR202)
    14d
    ATTAIN: Daratumumab and Belatacept for Desensitization (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab)
    19d
    Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature. (PubMed, J Med Case Rep)
    Venetoclax combination regimen achieved excellent efficacy and safety in the treatment of relapsed/refractory multiple myeloma with t(11;14) in this case. The treatment of patients with relapsed and refractory multiple myeloma with t(11;14) by venetoclax still needs to be confirmed by more clinical studies.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Darzalex (daratumumab) • dexamethasone
    20d
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    20d
    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • sonrotoclax (BGB-11417)